Company news
Tevogen Bio Holdings Inc. news in 2026
Tevogen Bio Holdings Inc.'s news releases, calls and decks from 2026, newest first.
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
October 8, 2026
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
October 8, 2026
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
September 30, 2026
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
July 13, 2026
Tevogen Announces Formation of a Healthcare Services Initiative
June 9, 2026
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
May 28, 2026
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
May 21, 2026
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
May 12, 2026
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
April 27, 2026
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
March 25, 2026
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 24, 2026
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
March 17, 2026
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
March 13, 2026
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
March 12, 2026
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
March 10, 2026
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
March 8, 2026
Letter to Shareholders from CEO Dr. Ryan Saadi
March 5, 2026
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
March 4, 2026
Tevogen Announces Reverse Stock Split
March 3, 2026
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
February 26, 2026
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
February 25, 2026
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
February 25, 2026
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
January 30, 2026
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
January 29, 2026
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
January 12, 2026